CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure

被引:422
作者
Rankovic, Zoran [1 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
CENTRAL-NERVOUS-SYSTEM; CANCER RESISTANCE PROTEIN; P-GLYCOPROTEIN TRANSPORT; IN-VITRO; MOLECULAR-SURFACE; TISSUE BINDING; PLASMA-PROTEIN; PHARMACOKINETIC MODEL; MEMBRANE-PERMEABILITY; RECEPTOR ANTAGONISTS;
D O I
10.1021/jm501535r
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The human brain is a uniquely: complex organ, which has evolved a sophisticated protection system to prevent injury from external insult and toxins. Designing molecules that can overcome this protection system and achieve optimal concentration at the desired therapeutic target in the brain is a:specific and major challenge for:medicinal chemists working in CNS drug discovery. Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drags and drug candidates. This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chemistry strategies toward molecules With optimal brain exposure. A, summary of modern CNS,pharmacokinetic concepts and. methods is also provided:
引用
收藏
页码:2584 / 2608
页数:25
相关论文
共 157 条
[122]   The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types [J].
Ritchie, Timothy J. ;
Macdonald, Simon J. F. ;
Young, Robert J. ;
Pickett, Stephen D. .
DRUG DISCOVERY TODAY, 2011, 16 (3-4) :164-171
[123]   Diphenhydramine Active Uptake at the Blood-Brain Barrier and Its Interaction with Oxycodone in Vitro and in Vivo [J].
Sadiq, Muhammad Waqas ;
Borgs, Annika ;
Okura, Takashi ;
Shimomura, Keita ;
Kato, Sayaka ;
Deguchi, Yoshiharu ;
Jansson, Britt ;
Bjorkman, Sven ;
Terasaki, Tetsuya ;
Hammarlund-Udenaes, Margareta .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) :3912-3923
[124]   Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins [J].
Schinkel, AH ;
Mayer, U ;
Wagenaar, E ;
Mol, CAAM ;
vanDeemter, L ;
Smit, JJM ;
vanderValk, MA ;
Voordouw, AC ;
Spits, H ;
vanTellingen, O ;
Zijlmans, JMJM ;
Fibbe, WE ;
Borst, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :4028-4033
[125]   Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein [J].
Seelbach, Melissa J. ;
Brooks, Tracy A. ;
Egleton, Richard D. ;
Davis, Thomas P. .
JOURNAL OF NEUROCHEMISTRY, 2007, 102 (05) :1677-1690
[126]   Integrating Intramolecular Hydrogen Bonding (IMHB) Considerations in Drug Discovery Using ΔlogP As a Tool [J].
Shalaeva, Marina ;
Caron, Giulia ;
Abramov, Yuriy A. ;
O'Connell, Thomas N. ;
Plummer, Mark S. ;
Yalamanchi, Geeta ;
Farley, Kathleen A. ;
Goetz, Gilles H. ;
Philippe, Laurence ;
Shapiro, Michael J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (12) :4870-4879
[127]   The P-glycoprotein efflux pump: How does it transport drugs? [J].
Sharom, FJ .
JOURNAL OF MEMBRANE BIOLOGY, 1997, 160 (03) :161-175
[128]   Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics [J].
Shen, DD ;
Artru, AA ;
Adkison, KK .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (12) :1825-1857
[129]   Estimation of ADME Properties with Substructure Pattern Recognition [J].
Shen, Jie ;
Cheng, Feixiong ;
Xu, You ;
Li, Weihua ;
Tang, Yun .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2010, 50 (06) :1034-1041
[130]   H-1 Antihistamines Current Status and Future Directions [J].
Simons, F. Estelle R. ;
Simons, Keith J. .
WORLD ALLERGY ORGANIZATION JOURNAL, 2008, 1 :145-155